

CITATION REPORT

List of articles citing

Osteonecrosis of the jaw in a patient on Denosumab

DOI: 10.1016/j.joms.2009.10.010

Journal of Oral and Maxillofacial Surgery, 2010, 68, 959-63.

Source: <https://exaly.com/paper-pdf/48001837/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
214	... Fracture prevention. New osteoporosis drug improves patient adherence. 2010 , 23, 56, 60		1
213	How new knowledge sounds: developing a contemporary understanding of osteonecrosis. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010 , 68, 957-8	1.8	4
212	Current awareness: Pharmacoepidemiology and drug safety. 2010 , 19, i-xii		0
211	Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible. 2010 , 13, 214-22		30
210	Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation. 2010 , Volume 2, 49-69		
209	Denosumab. 2010 , 45, 785-796		2
208	Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. 2010 , 12, 214		57
207	Alendronic acid/denosumab interaction. 2010 , &NA;, 9-10		
206	First reports of serious adverse drug reactions in recent weeks. 2010 , 26, 22-23		
205	Prevention of osteoporosis: one step forward, two steps back. 2011 , 17, 137-41		10
204	Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. 2011 , 39, 272-7		92
203	Osteonecrosis of the jaws: what the physician needs to know: practical considerations. 2011 , 57, 231-41		5
202	Denosumab and bisphosphonates: different mechanisms of action and effects. 2011 , 48, 677-92		445
201	Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws?. 2011 , 77, 905-11		22
200	Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data. 2011 , 1, 1695-1706		20
199	Emerging therapeutic opportunities for skeletal restoration. 2011 , 10, 141-56		108
198	Bone Biology for Implant Dentistry in Atrophic Alveolar Ridge - Theory and Practice. 2011 ,		

197	Denosumab: a novel biological therapy for osteoporosis. 2011 , 7, 13-43	
196	Bisphosphonate-related osteonecrosis of the jaw: an overview. 2011 , 1218, 38-46	83
195	Potential pathophysiological mechanisms in osteonecrosis of the jaw. 2011 , 1218, 62-79	115
194	Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011 , 69, 959-960	1.8 0
193	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. 2011 , 31, 510-23	25
192	Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. 2011 , 33, 1547-59	32
191	The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. 2011 , 99, 8-17	36
190	Current and future treatment options in osteoporosis. 2011 , 67, 321-331	30
189	Bisphosphonates and Osteonecrosis of the Jaws: A Review of Clinical Features and the Drug Effect on Oral Soft Tissues. 2011 , 9, 38-46	1
188	Animal Models of Osteonecrosis. 2011 , 9, 63-80	10
187	Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. 2011 , 26, 1871-82	154
186	Current world literature. 2011 , 5, 297-305	
185	Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations. 2011 , 22 Suppl 1, i44-9	21
184	The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. 2011 , 16, 651-62	47
183	Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. 2011 , 142, 1243-51	242
182	Osteonecrosis of the jaw: Recent clinical and preclinical advances. 2011 , 8, 141-153	3
181	Denosumab-related osteonecrosis of the jaw. 2012 , 143, 981-4	57
180	TOOTH SURFACE LOSS: Authors' response. 2012 , 143, 730-732	

179	Recommendations questioned. 2012 , 143, 732, 734; author reply 734		
178	New insights into osteoporosis: the bone-fat connection. 2012 , 272, 317-29		180
177	What's new in primary bone tumors. 2012 , 94, 1913-9		25
176	Pathophysiology and pharmacologic control of osseous mandibular condylar resorption. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 1918-34	1.8	94
175	Risks for jaw osteonecrosis drastically increases after 2 years of bisphosphonate therapy. 2012 , 12, 251-3		2
174	Risks for jaw osteonecrosis drastically increases after 2 years of bisphosphonate therapy. 2012 , 12, 116-8		4
173	The relationship of denosumab pharmacology and osteonecrosis of the jaws. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012 , 114, 671-6	2	53
172	In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. 2012 , 7, e44868		4
171	Introduction. 2012 , 1-11		
170	BRONJ: The Future. 2012 , 167-178		
169	Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. 2012 , 16, 1143-52		44
168	Osteoporosis and osteopenia: implications for periodontal and implant therapy. 2012 , 59, 111-39		31
167	Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. 2012 , 18, 602-12		37
166	Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone. <i>Journal of Oral and Maxillofacial Surgery</i> , 2013 , 71, 1017-26	1.8	30
165	Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 2013 , 90, 441-68		34
164	Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. 2013 , 41, 694-8		63
163	Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals. 2013 , 49, 878-886		34
162	Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. 2013 , 33, 2189-98		7

161	Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2013 , 71, 513-9	1.8	23
160	An office-based approach to the diagnosis and management of osteonecrosis. 2013 , 21, 167-73		7
159	Denosumab osteonecrosis of the mandible: a new entity? A case report. 2013 , 41, e65-9		33
158	Review of current literature and implications of RANKL inhibitors for oral health care providers. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013 , 116, e437-42	2	26
157	Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients. 2013 , 25, 123-128		8
156	Bone Marrow Fat and Bone Mass. 2013 , 167-179		1
155	Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw. 2013 , 10, 1-8		30
154	Emerging concepts in the management and treatment of osteonecrosis of the jaw. 2013 , 25, 11-20, v		26
153	Multiple myeloma: the bone marrow microenvironment and its relation to treatment. 2013 , 70, 110-20		40
152	Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition. 2013 , 18, e194-200		5
151	Osteonecrosis of the jaw: BRONJ and ARONJ. 2014 , 5, 90-93		8
150	Osteochemonecrosis: an overview. 2014 , 8, 482-90		13
149	Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model. 2014 , 68, 11-9		50
148	Abstracts of the 19th Annual Congress of the Belgian Society of Internal Medicine, December 12-13, 2014, Brussels, Belgium. 2014 , 69 Suppl 3, S4-S26		
147	Pharmacology. 2014 , 29-64		
146	Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. 2014 , 59, 516-9		38
145	Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF- κ B ligand antibody in mice. 2014 , 184, 3084-93		62
144	A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1456-62	1.8	34

143	Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1957-65	1.8	14
142	Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. 2014 , 52, 308-13		30
141	Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. 2014 , 25, 393-5		34
140	Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?. 2014 , 140, 487-93		13
139	Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. 2014 , 14, e15-21		47
138	The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. 2014 , 26, 231-7		6
137	American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1938-56	1.8	1448
136	Diverse osteoclastogenesis of bone marrow from mandible versus long bone. 2014 , 85, 829-36		20
135	Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned. 2014 , 26, 171-91		12
134	Unhealed tooth extraction wound in a breast cancer patient. 2014 , 43, 1024-5		3
133	Stage 0 osteonecrosis of the jaw in a patient on denosumab. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 702-16	1.8	24
132	A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field. 2014 , 29, e45-57		24
131	The mechanisms of bone destruction in periodontitis -the factors of osteoclast formation and activation-. 2015 , 57, 120-125		
130	RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. 2015 , 59, 2455		14
129	Osteonecrosis of the jaw a new complication related to Ipilimumab. 2015 , 51, e100-1		23
128	Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. 2015 , 60, 557-65		18
127	Giant cell tumour of bone: new treatments in development. 2015 , 17, 419-30		57
126	A radiological approach to benign and malignant lesions of the mandible. 2015 , 70, 335-50		21

125	Drug induced osteonecrosis of the jaw. 2015 , 41, 455-64	55
124	Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. 2015 , 21, 927-36	24
123	Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 120, 548-53	2 19
122	Bisphosphonate and Implant Dentistry - Is it Safe?. 2015 , 4, 30-3	5
121	Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw. 2015 , 27, 479-87	41
120	Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates. 2015 , 27, 497-508	21
119	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. 2015 , 30, 3-23	680
118	Medication-Related Osteonecrosis of the Jaws. 2015 ,	3
117	Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. 2015 , 51, 62-74	61
116	Treatment of post-menopausal osteoporosis: beyond bisphosphonates. 2015 , 38, 13-29	51
115	A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw. 2016 , 25, 447-454	4
114	Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. 2016 , 21, e431-9	14
113	Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case. 2016 , 2016, 5070187	12
112	Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. 2016 , 2016, 8768162	34
111	Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report. 2016 , 27, 353-8	12
110	Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. 2016 , 42, 271-277	8
109	Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database. 2016 , 30, 450-8	8
108	Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach. 2016 , 36, 231-6	6

107	Gnathodiaphyseal dysplasia: report of a family with a novel mutation of the ANO5 gene. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016 , 121, e123-8	2	15
106	Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates. 2016 , 14, 219-25		10
105	Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. 2016 , 20, 305-314		31
104	Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. 2016 , 27, 367-75		78
103	An unusual case of osteonecrosis of the jaw associated with dengue fever and periodontitis. 2016 , 61, 113-119		3
102	Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016 , 122, 272-8	2	14
101	Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases. 2016 , 4, 191-194		10
100	Septic shock associated with denosumab-related osteonecrosis of the jaw: A case report and literature review. 2016 , 28, 228-233		
99	Does Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography Facilitate Treatment of Medication-Related Osteonecrosis of the Jaw?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016 , 74, 945-58	1.8	17
98	Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. 2016 , 44, 265-70		16
97	Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. 2017 , 21, 127-134		23
96	Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. 2017 , 105, 484-493		15
95	Antiresorptive treatment-associated ONJ. 2017 , 26, e12787		7
94	Further development of the MRONJ minipig large animal model. 2017 , 45, 1503-1514		27
93	Selective Percutaneous Controlled Radiofrequency Thermocoagulation of the Gasserian Ganglion To Control Facial Pain Due to Medication-Related Osteonecrosis of the Jaw. 2017 , 20, 1171-1174		3
92	Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. 2017 , 15, 128		26
91	Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro. 2017 , 21, 1979-1988		20
90	Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2017 , 75, 129-142	1.8	34

89 Appendix: Suggested Reading. **2017**, 699-741

88 Anti-resorptive treatment in osteoporosis and their deleterious effects on maxillary bone metabolism in clinical dentistry. **2017**, 185-209

87 Denosumab - a new medication in the treatment of postmenopausal osteoporosis. **2017**, 16, 75-78

86 Regulatory Perspectives in Pharmacometric Models of Osteoporosis. **2018**, 58, 572-585

7

85 CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. **2018**, 47, 20170323

23

84 Neoadjuvant denosumab for the treatment of a sacral osteoblastoma. **2018**, 27, 446-452

6

83 Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. **2018**, 22, 597-615

43

82 Denosumab as a potential treatment alternative for patients suffering from diffuse sclerosing osteomyelitis of the mandible-A rapid communication. **2018**, 46, 534-537

13

81 Denosumab-related osteonecrosis of the jaw: A retrospective study. **2018**, 47, 66-70

24

80 Transplantation of Noncultured Stromal Vascular Fraction Cells of Adipose Tissue Ameliorates Osteonecrosis of the Jaw-Like Lesions in Mice. **2018**, 33, 154-166

29

79 Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2018**, 126, 537-544

19

78 Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series. **2018**, 46, 1515-1525

36

77 Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2018**, 126, e208-e211

2

7

76 Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. **2019**, 36, 313-324

13

75 From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights. **2019**, 20,

26

74 Medication-related osteonecrosis of the jaw: A literature review. **2019**, 61, 99-104

41

73 Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review. **2019**, 64, 122-134

14

72 Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw. **2019**, 30, e434-e436

7

71	A Novel, Tumor-Induced Osteoclastogenesis Pathway Insensitive to Denosumab but Interfered by Cannabidiol. 2019 , 20,		3
70	Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis. 2019 , 34, 171-181		15
69	Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019 , 127, 117-135	2	97
68	Uncertainty managing patients treated with antiresorptive drugs: a cross-sectional study of attitudes and self-reported behavior among dentists in Sweden. 2020 , 78, 109-117		
67	Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. 2020 , 49, 298-309		6
66	A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020 , 129, 411-417	2	11
65	Adjuvant therapies for MRONJ: A systematic review. 2020 , 141, 115676		8
64	Dynamic polarization shifting from M1 to M2 macrophages in reduced osteonecrosis of the jaw-like lesions by cessation of anti-RANKL antibody in mice. 2020 , 141, 115560		9
63	Medication-Related Osteonecrosis of the Jaw: An Overview. 2020 ,		
62	Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. 2020 , 9,		16
61	Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. 2020 , 228, 886-892		5
60	Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy. 2020 , 28, 771-778		3
59	Current Concepts of Osteomyelitis: From Pathologic Mechanisms to Advanced Research Methods. 2020 , 190, 1151-1163		19
58	Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review. 2020 , 48, 435-443		19
57	Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. 2020 , 135, 115308		14
56	Oral biosciences: The annual review 2019. 2020 , 62, 1-8		
55	Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. 2020 , 13,		5
54	Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression. 2020 , 58, 473-489		3

53	Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw. 2020 , 10, 5620		8
52	Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management. 2021 , 105, 170-187		4
51	Should denosumab treatment for osteoporosis be continued indefinitely?. 2021 , 12, 20420188211010052		1
50	Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ). 2021 , 57,		3
49	Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency. 2021 , 13,		3
48	Adverse events associated with bone-directed therapies in patients with cancer. 2021 , 115901		3
47	Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report. 2021 , 12, e12		2
46	Comparing the Surgical Response of Bisphosphonate-Related Versus Denosumab-Related Osteonecrosis of the Jaws. <i>Journal of Oral and Maxillofacial Surgery</i> , 2021 , 79, 1045-1052	1.8	0
45	Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. 2021 , 7, 47		8
44	Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). 2021 , 57,		12
43	Local RANKL delivery improves socket healing in bisphosphonate treated rats. 2021 , 148, 115945		1
42	Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner. 2021 , 1		5
41	Epidemiology of Medication-Related Osteonecrosis of the Jaw. 2015 , 55-61		1
40	Treatment of Medication-Related Osteonecrosis of the Jaw. 2015 , 79-91		1
39	Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). 2020 ,		0
38	[Denosumab for treatment of postmenopausal osteoporosis]. 2011 , 131, 1893-6		2
37	Osteonecrosis of jaw associated with bisphosphonate use. 2012 , 16, 450-2		6
36	Photodynamic Therapy for Medication-Related Osteonecrosis of the Jaws: A Case Report. 2016 , 07, 824-828		2

35	Osteonecrosis of the jaws in patients treated with bisphosphonates. 2012 , 4, e60-5	5
34	Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. 2020 , 25, e326-e336	26
33	Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw. 2021 , 36, 917-927	2
32	Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw. 2014 , 03, 1-5	
31	Animal Models of Medication-Related Osteonecrosis of the Jaw. 2015 , 155-167	0
30	Histopathology of Medication-Related Osteonecrosis of the Jaw. 2015 , 131-137	
29	Definition, Clinical Features and Staging of Medication-Related Osteonecrosis of the Jaw. 2015 , 43-54	
28	[Current approaches for early detection and treatment of medication-related osteonecrosis of jaw]. 2014 , 155, 1960-6	
27	Imaging avascular necrosis of bone: "The shifting paradigm". 2016 , 31, 1-2	
26	Etiology and Treatment of Bisphosphonate-related Osteonecrosis of the Jaw. 2018 , 9, 11-14	
25	Denosumab efficacy in giant cell tumors of the bone - short review. 2018 , 1, 109-111	
24	Republished: Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. 2020 , 58, 172-175	
23	Pulpal Disease Arising from Medication-related Osteonecrosis of the Jaw: A Case Report. 2020 , 46, 1149-1154	1
22	How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network. 2015 , 63, 61-7	
21	Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents. 2016 , 59, 45-53	4
20	Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. 2021 , 1	1
19	Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings. 2021 , 1	0
18	Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.. 2021 , 28, 279-296	3

17	Medication-related osteonecrosis of the jaw: An update. 2022 ,		0
16	Diagnosis and Treatment of Lumbar Giant Cell Tumor of the Spine: Update on Current Management Strategies.. 2022 , 12,		0
15	Medication-Related Osteonecrosis of the Jaws: A Literature Review. 2022 , 47, 1-9		
14	Regulation of TNF-Induced Osteoclast Differentiation.. <i>Cells</i> , 2021 , 11,	7.9	5
13	Effects of Soft Tissue Closure on Medication-Related Osteonecrosis of the Jaw in a Rabbit Model with Tooth Extraction: A Pilot Study.. <i>BioMed Research International</i> , 2021 , 2021, 4166770	3	
12	Anti-RANKL Inhibits Thymic Function and Causes DRONJ in Mice.. <i>International Journal of Dentistry</i> , 2022 , 2022, 9299602	1.9	
11	Lansoprazole and zoledronate delays hard tissue healing of tooth extraction sockets in dexamethasone-treated mice.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 150, 112991	7.5	
10	Incidence and risk factors associated to Medication-Related OsteoNecrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022 ,	1.7	0
9	Actinomycosis and osteonecrosis of the jaw: Every why hides a why. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022 ,	1.7	
8	Locally Delivered Metabolite Derivative Promotes Bone Regeneration in Aged Mice. <i>ACS Applied Bio Materials</i> ,	4.1	
7	Assessment of Clinical Guidelines for Medication-Related Osteonecrosis of the Jaw: Current Status and Future Directions. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2022 ,	2	
6	Medication-related osteonecrosis of the jaw: A literature review and update. 2022 , 60,		1
5	Dental Consideration in Patients Under Bisphosphonate and Radiotherapy: Systematic Review□		0
4	Complications and prognosis of primary thoracic and lumbar giant cell tumors treated by total tumor resection. 2023 , 24,		0
3	Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients▣ Systematic Review. 2023 , 12, 1416		0
2	Evaluation of the anti-RANKL monoclonal antibody in rheumatoid arthritis rats. 2023 , 38, 22-31		0
1	Risk factors and CT findings associated with treatment outcomes in patients with medication-related osteonecrosis of the jaw: A retrospective study.		0